25-hydroxycholesterol disulfate | 1467725-76-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 25-hydroxycholesterol disulfate
• 英文别名: [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methyl-6-sulfooxyheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
• CAS: 1467725-76-3
• 化学式: C₂₇H₄₆O₈S₂
• 分子量: 562.789
• InChiKey: OCDVCNCLHWDVFM-ZHHJOTBYSA-N

物化性质

• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  25-羟基胆甾醇 在 吡啶 、 sulfur trioxide-trimethylamine complex 作用下， 反应 1.0h， 以60%的产率得到25-hydroxycholesterol disulfate
  参考文献：
  名称：

  [EN] A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3beta-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS
  [FR] NOUVEAU MÉTABOLITE DU CHOLESTÉROL, 5-CHOLESTÈNE, 3Beta-25-DIOL, DISULFATE (25HCDS) POUR LA THÉRAPIE DE TROUBLES MÉTABOLIQUES, DE L'HYPERLIPIDÉMIE, DU DIABÈTE, DES STÉATOSES HÉPATIQUES ET DE L'ATHÉROSCLÉROSE

  摘要：

  5-胆甾烷，3β，25-二醇，二硫酸酯（25HCDS）已被发现是一种真正的PPARϒ激动剂和LXR拮抗剂，并用于治疗脂质代谢紊乱和炎症性疾病，包括但不限于脂肪肝，炎症性肠病和动脉粥样硬化疾病。

  公开号：

  WO2013154752A1

文献信息

• COMPOSITIONS FOR THE TREATMENT OF CATARACTS
  申请人：Catacore, Inc.

  公开号：US20170027961A1

  公开（公告）日：2017-02-02

  In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ 7,24 -cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO 3 H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO 3 H,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.
• [EN] A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3beta-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS<br/>[FR] NOUVEAU MÉTABOLITE DU CHOLESTÉROL, 5-CHOLESTÈNE, 3Beta-25-DIOL, DISULFATE (25HCDS) POUR LA THÉRAPIE DE TROUBLES MÉTABOLIQUES, DE L'HYPERLIPIDÉMIE, DU DIABÈTE, DES STÉATOSES HÉPATIQUES ET DE L'ATHÉROSCLÉROSE
  申请人：VIRGINA COMMONWEALTH UNIVERSITY

  公开号：WO2013154752A1

  公开（公告）日：2013-10-17

  5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARϒ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.

  5-胆甾烷，3β，25-二醇，二硫酸酯（25HCDS）已被发现是一种真正的PPARϒ激动剂和LXR拮抗剂，并用于治疗脂质代谢紊乱和炎症性疾病，包括但不限于脂肪肝，炎症性肠病和动脉粥样硬化疾病。